摘要: Many public and private efforts in coming years will focus on research precision medicine, developing biomarkers to indicate which patients are likely benefit from a certain treatment so that others can be spared the cost—financial physical—of being treated with unproductive therapies therapeutic signals more easily uncovered. However, such initiatives alone not deliver new medicines absence of strong incentives bring products market. We examine unique economics associated biomarkers, an emphasis factors affecting their development, pricing, access.
sciencemag.org
harvard.edu参考文章(12)
D. Acemoglu, J. Linn, Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry Quarterly Journal of Economics. ,vol. 119, pp. 1049- 1090 ,(2004) , 10.1162/0033553041502144
AD Barker, CC Sigman, GJ Kelloff, NM Hylton, DA Berry, LJ Esserman, I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy Clinical Pharmacology & Therapeutics. ,vol. 86, pp. 97- 100 ,(2009) , 10.1038/CLPT.2009.68
John H. Cochrane, Time-Consistent Health Insurance Journal of Political Economy. ,vol. 103, pp. 445- 473 ,(1995) , 10.1086/261991
Scott M. Berry, Jason T. Connor, Roger J. Lewis, The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments JAMA. ,vol. 313, pp. 1619- 1620 ,(2015) , 10.1001/JAMA.2015.2316
Peter B. Bach, Indication-Specific Pricing for Cancer Drugs JAMA. ,vol. 312, pp. 1629- 1630 ,(2014) , 10.1001/JAMA.2014.13235
Pierre Dubois, Olivier de Mouzon, Fiona Scott‐Morton, Paul Seabright, Market Size and Pharmaceutical Innovation The RAND Journal of Economics. ,vol. 46, pp. 844- 871 ,(2015) , 10.1111/1756-2171.12113
Wesley Yin, R&D policy, agency costs and innovation in personalized medicine. Journal of Health Economics. ,vol. 28, pp. 950- 962 ,(2009) , 10.1016/J.JHEALECO.2009.06.011
Amitabh Chandra, Anupam B Jena, Jonathan S Skinner, The pragmatist's guide to comparative effectiveness research. Journal of Economic Perspectives. ,vol. 25, pp. 27- 46 ,(2011) , 10.1257/JEP.25.2.27
Amitabh Chandra, Jacqueline Vanderpuye-Orgle, Competition in the Age of Biosimilars JAMA. ,vol. 314, pp. 225- 226 ,(2015) , 10.1001/JAMA.2015.6170
Vahid Montazerhodjat, David M. Weinstock, Andrew W. Lo, Buying cures versus renting health: Financing health care with consumer loans Science Translational Medicine. ,vol. 8, ,(2016) , 10.1126/SCITRANSLMED.AAD6913